Tempus AI shares are trading higher Monday morning. The company announced it has received U.S. Food and Drug Administration 510(k) clearance for its RNA-based Tempus xR IVD device.
Tempus AI shares are trading higher Monday morning. The company announced it has received U.S. Food and Drug Administration 510(k) clearance for its RNA-based Tempus xR IVD device.
Copyright © Louis Velazquez. All Rights Reserved.